FCGR3A and Hodgkins lymphoma: Nieto, et al., reported excellent ORR (including 67% complete responses) in patients with treatment-refractory Hodgkin lymphoma (HL) treated with the combination of a CD30-CD16A bispecific antibody (AFM13) and cord-blood-derived NK cells [244].